Canadian scientists made one of the most important discoveries in the history ofmedicine 100 years agowhen Dr. Frederick Banting and his assistant, Charles Best, successfully isolated the hormone insulin in Banting's lab at the University of Toronto.
On November 14th, 1921, the team presented their findings to fellow faculty members and students: they had successfully discovered a treatment for diabetes. It soon found its way to millions of patients, transforming the disease from a death sentence into a manageable, chronic condition.
However, a century later, despite technological advancements, treatment for Type 1 diabetes still often requires invasive and inconvenient treatment, something that biomedical researchers are actively trying to change.
"It's an important achievement, but ultimately, we're still injecting ourselves with insulin," said Michael Sefton, the executive director of Medicine by Design, an incubator for medical breakthroughs based atthe University of Toronto,where he's also a professor of biomedical engineering.
Working at the same institution whereBanting and Best did a century ago, Sefton is a part of a team trying to find a cure for diabetes so that patients no longerrequire daily injections.
"It is kind of in the woodwork here, trying to sort of continue to work on insulin. But it's maybe a little disappointing that we're still talking about the problems of insulin delivery 100 years later," he said.
Prior to Banting and Best's discovery, diabetes was uncontrollable, and often fatal within a year of diagnosis. The only treatment that could delay the inevitable was a rigorous near-starvation diet.
Insulin is the vital hormone that the body uses to managehow it turns food into energy. Without insulin, blood sugar cannot be properly regulated. High blood sugar levels can damage blood vessels, leading to blindness, renal failureor heart attacks. Dangerously low levels can lead to diabetic coma and death.
Type 1 diabetes, which used to be called juvenile diabetes, happens when the pancreas produces little to no insulin at all. "It's an autoimmune disease, so your immune system has turned on your own islets, the insulin secreting cells, and destroys them," said Sefton.
In Type 2 diabetes, the much more common version of the disease, the body doesn't respond properly to the insulin it makes. That's known asinsulin resistance. As the disease progresses, the pancreas makes less and less insulin, and patients require more insulin supplementation as a result.
Isolating insulin was an important discovery because it meant that there was a form of treatment beyond a starvation diet. But in later interviews, Best said he wanted to improve on the delivery method.
"I think we'll get much better ways of giving it," said Best on CBC's Morningside in a 1977 interview. "There's work going on here and in other places about an artificial pancreas, which if it can be miniaturized, put under the skin, it would discharge insulin just when it was needed. Or if the cultures of an artificial pancreas could be grafted and the cells which make insulin kept alive, that would do away with the injections."
However, he added, "I don't think either of those are going to happen very soon."
Best was correct. Even decades after his death, work on these technologies is still ongoing, although Sefton believes that better treatments are on the horizon.
After training as an engineer, Sefton started working on diabetesin the 1970s, when there was great interest in building a mechanical pancreas thatcould sense insulin levels and release the hormone as needed.
"We wondered whether the best available glucose sensors were the cells themselves, the normal pancreas cells, what we call the pancreatic islets," hetold Quirks & Quarks host Bob McDonald. "And so the question was, could we transplant pancreatic islets from a normal individual into a diabetic and make them replace the pancreas?"
Sefton's work builds on a 20-year-old surgical procedure called The Edmonton Protocol, where researchersfound that implanting donated islet cells into a diabetic patient's liver would allow them to make their own insulin for a period of time. However, in all patients, their diabetes eventually returned.
"The challenge with the liver is it is a somewhat hostile environment for the islets, and so only maybe 60 percent of the islets that are transplanted survive," said Sefton.
His work focuses on using the skin as a transplant site for the islets, as a site that's less invasive for researchers to access, and less hostile to the foreign cells.
By injecting the islets under the skin with a material called methacrylic acid, or MAA, researchers have found that the body createsnew blood vessels around the cells, enabling them to deliver insulin throughout the body. "Because those are blood vessels that are grown under the skin, the islets will ingraft, and will function as they are supposed to function," said Sefton.
He is also working to create stem cell derived islets, to make the cells easier to obtain than relying on donor cells. "The cells that are derived from stem cells work almost the same as the donated islets. That's the beauty of them. But we aren't necessarily very good at that yet.It's still early days."
Sefton believes islet treatments will be a possibility for humanswithin 20 years. And looking forward to the next 100 years of diabetes treatment, Sefton is optimistic.
"I'm not shy, so I would say it'll be a disease of the past," he said.
Produced and written by Amanda Buckiewicz.
Read the original here:
- Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive - January 16th, 2022
- Trial of Cell Therapy to Raise HbF Levels Showing Potential, But... - Sickle Cell Anemia News - January 16th, 2022
- What it's like in academic family medicine: Shadowing Dr. Rouhbakhsh - American Medical Association - January 16th, 2022
- The Fusion of mRNA and Immunotherapy - NEO.LIFE - January 16th, 2022
- Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference - The Bakersfield Californian - January 11th, 2022
- BioCardia Announces Participation at the Upcoming Digital Medicine & Medtech Showcase and the H.C. Wainwright BioConnect Virtual Conference -... - January 11th, 2022
- Equillium Announces Multiple Abstracts Accepted for Presentation at the Transplantation & Cellular Meetings of ASTCT and CIBMTR - Yahoo Finance - January 11th, 2022
- Houston TX Diabetes Stem Cell Treatment Regenerative Medicine Therapy Launch - Digital Journal - January 9th, 2022
- Stem Cell Rejuvenation Center - January 9th, 2022
- Cartesian Aims to Propel RNA Cell Therapy with Combinations - BioSpace - January 9th, 2022
- Orthopedic Biomaterials Product Market: Hip implant product segment is anticipated to carry major share of the market - BioSpace - January 9th, 2022
- Gamida Cell Announces Data to be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem Meetings - Business Wire - January 9th, 2022
- Jakubowiak Talks Daratumumab Quadruplet Therapy and the GRIFFIN Study at 2021 ASH - Cancer Network - January 9th, 2022
- Part 1: Benefit Shown With Transplant and Combination Therapy in Multiple Myeloma - Targeted Oncology - January 9th, 2022
- Notch Therapeutics' Peter Zandstra Appointed to the Order of Canada - Yahoo Finance - January 7th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVirs Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults... - January 7th, 2022
- BlueRock Therapeutics Announces Closeout of First Cohort in Phase 1 Trial in Patients with Advanced Parkinson's Disease - Yahoo Finance - January 7th, 2022
- Cellusion Raises 1.1B JPY to Advance Japan and Global Clinical Trials of CLS001 for Corneal Endothelial Cell Regenerative Therapy - Galveston County... - January 7th, 2022
- US FDA approves Phase 3 Study Design for Zilovertamab in the Treatment of Mantle Cell Lymphoma - OncoZine - January 5th, 2022
- Alzheimer's Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases - PRNewswire - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy Designation To AlloVir's Posoleucel For The Treatment Of Adenovirus Infections In Adults And... - January 5th, 2022
- Protecting people with cancer from COVID-19: - EurekAlert - January 5th, 2022
- Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual JP Morgan Healthcare Conference - TheNewswire.ca - January 5th, 2022
- Placental Stem Cell Therapy Market to Surpass US$ 4.4 Bn by 2030, Underpinned by Enormous R&D in Cellular Therapies and Regenerative Medicine, Finds... - January 3rd, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - AsiaOne - January 3rd, 2022
- Genomic variant may help predict which patients will experience chemotherapy-induced cardiotoxicity - News-Medical.Net - January 3rd, 2022
- lodie Yung plunges into the undocumented underworld in 'The Cleaning Lady' - Entertainment Weekly News - January 3rd, 2022
- Cellular Therapies Fill Unmet Needs in R/R Multiple Myeloma - Targeted Oncology - January 2nd, 2022
- Curi Bio Closes $10M Series A in Oversubscribed Round - BioSpace - December 31st, 2021
- Bring in the bulldozers: Cynatas CEO on how heavyweight FujiFilm will turbocharge its ... - Stockhead - December 31st, 2021
- Questions on Quadruplets and CAR T Set to be Answered As Myeloma Paradigm Parses Out the Clinical Value of MRD - OncLive - December 31st, 2021
- Stem Cell Therapy NYC, Regenerative Medicine Injections ... - December 29th, 2021
- James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy - MD Magazine - December 29th, 2021
- Global Automated and Closed Cell Therapy Processing Systems - GlobeNewswire - December 29th, 2021
- Bill would pave way for organ donation - Stabroek News - December 29th, 2021
- Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML - BioSpace - December 29th, 2021
- Valemetostat New Drug Application Submitted in Japan for Treatment of Patients with Adult T-Cell Leukemia/Lymphoma - Business Wire - December 29th, 2021
- 2021: The Year in Diabetes - Healthline - December 29th, 2021
- Covid infects kidneys and leads to scarring: Study - India New England - December 29th, 2021
- Fetal Gut May Have Insulin-Producing Cells That Shut Off at Birth - Medscape - December 29th, 2021
- Brem Looks at Multiple Treatments for Patients With DLBCL - Targeted Oncology - December 26th, 2021
- Delete Blood Cancer! How Content Creator Duo Abhi And Niyu Inspired Thousands To Give Someone Second... - The Logical Indian - December 25th, 2021
- The pathogenesis, natural history, and treatment of type 1 diabetes: time (thankfully) does not stand still - The Lancet - December 25th, 2021
- Ropinirole Proves Safe and Tolerable for Patients With ALS - Medscape - December 25th, 2021
- Major international research center may drive the development of future stem cell-based treatments - News-Medical.Net - December 19th, 2021
- Receiving CAR-T therapy sooner improves lymphoma survival, according to study published in New England Journal of Medicine - Newswise - December 19th, 2021
- Latest Cancer Research: CAR T to Liquid Biopsies - Healthline - December 19th, 2021
- Trials of stem cell therapy offer hope to childless women in Bangladesh - The Financial Express BD - December 19th, 2021
- UC San Diego Breaks Ground on Revitalization of Hillcrest Campus - UC San Diego Health - December 19th, 2021
- BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition -... - December 19th, 2021
- CAR-T Cell Therapy Continues to Impress in Myeloma Treatment - Curetoday.com - December 17th, 2021
- CAR-T therapy trials show promise for earlier use in lymphoma - BioPharma Dive - December 17th, 2021
- Cedars-Sinai researchers discover growth hormone in the colon that influences aging process - News-Medical.Net - December 17th, 2021
- Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors - Business Wire - December 17th, 2021
- BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin's Fast Onset Mechanism of Action in the Prevention of... - December 17th, 2021
- CAR T-Cell Therapy for Large B-Cell Lymphoma Who, When, and How? | NEJM - nejm.org - December 15th, 2021
- Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine... - December 15th, 2021
- AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders -... - December 15th, 2021
- Bioengineered skin breakthrough to revolutionise burns treatment - Medicine, Nursing and Health Sciences - Monash University - December 15th, 2021
- In Patients With Acute GVHD, First-Line Itolizumab Associated With High Rates of Clinical Response, Tolerability - Targeted Oncology - December 15th, 2021
- BrainStorm Cell Therapeutics Announces peer reviewed publication of NurOwn's Phase 3 Study for ALS in Muscle and Nerve - BioSpace - December 15th, 2021
- Flawed genetic switches could be at the origin of malformations or developmental diseases - News-Medical.net - December 15th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - BioSpace - December 9th, 2021
- Syrian refugee is thriving five years after last-gasp gene therapy - STAT - STAT - December 9th, 2021
- What happened to Dolly the sheep? How long the first cloned adult mammal lived, and her legacy explained - iNews - December 9th, 2021
- It is imperative to reduce the cost of cancer treatment: Ramesh Ramadurai, MD, 3M India - ETHealthworld.com - December 9th, 2021
- For the 2nd time listed as the World's Top 2% scientists by Stanford University - Malaysiakini - December 9th, 2021
- Research offers a phylogenetic and ontogenetic overview of the primitive streak - News-Medical.net - December 7th, 2021
- New discoveries make steps toward lipoedema diagnosis and treatment - Mirage News - December 7th, 2021
- With its Parkinsons treatment, TreeFrog Therapeutics shows cell therapy is no longer science fiction - The Times Hub - December 7th, 2021
- The lung game: is hyperbaric oxygen therapy any good? - Financial Times - December 7th, 2021
- Irving Weissman Laboratory | Institute for Stem Cell ... - December 4th, 2021
- Nine Things To Know About Stem Cell Treatments - A Closer ... - December 4th, 2021
- Regenerative Medicine & Stem Cell Therapy Las Vegas ... - December 4th, 2021
- World AIDS Day: is a cure for HIV finally in sight? - Thomson Reuters Foundation - December 4th, 2021
- New genetic technology for gene expression analysis of cancer cells - News-Medical.net - December 4th, 2021
- Stem Cell Therapy Restores Insulin Production in Patients with Type 1 Diabetes - MD Magazine - December 4th, 2021
- It takes guts to make a heart - EurekAlert - December 4th, 2021
- Appia Bio Announces Appointment of Irving Weissman, MD, and Mark Exley, PhD, to Scientific Advisory Board - BioSpace - December 4th, 2021
- The Intramural Research Program at the Abu Dhabi Stem Cell Center (ADSCC) Signs a Letter of Intent to Collaborate with the Division of Intramural... - December 4th, 2021